Abivax S.A. SEC filings ABVX
Abivax S.A. has 105 filings in SEC EDGAR's recent list, going back to Dec 16, 2022. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 21, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-6EF | Filing | Sep 21, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 21, 2026 | Jun 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 6, 2026 | — |
| 6-K | Current report (foreign issuer) | Jul 2, 2026 | Jul 2, 2026 |
| 424B5 | Prospectus supplement | Jul 2, 2026 | — |
| FWP | Free writing prospectus | Jul 1, 2026 | — |
| FWP | Free writing prospectus | Jun 30, 2026 | — |
| 424B5 | Prospectus supplement | Jun 30, 2026 | — |
| POSASR | Filing | Jun 30, 2026 | — |
| 6-K | Current report (foreign issuer) | Jun 29, 2026 | Jun 29, 2026 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 1, 2026 |
| 6-K | Current report (foreign issuer) | May 22, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | May 20, 2026 | May 20, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 11, 2026 | — |
| 6-K | Current report (foreign issuer) | May 7, 2026 | May 7, 2026 |
| 424B7 | Filing | May 7, 2026 | — |
| 6-K | Current report (foreign issuer) | Apr 20, 2026 | Apr 20, 2026 |
| S-8 | Employee stock plan registration | Mar 23, 2026 | — |
| 20-F | Annual report (foreign issuer) | Mar 23, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 23, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Feb 23, 2026 | Feb 21, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 14, 2026 | — |
| 144 | Notice of proposed sale | Jan 8, 2026 | — |
| 6-K | Current report (foreign issuer) | Dec 15, 2025 | Sep 30, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 30, 2025 | — |
| 144 | Notice of proposed sale | Oct 28, 2025 | — |
| 6-K | Current report (foreign issuer) | Sep 8, 2025 | Jun 30, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 31, 2025 | — |
| 424B5 | Prospectus supplement | Jul 24, 2025 | — |
| 6-K | Current report (foreign issuer) | Jul 24, 2025 | Jul 24, 2025 |
| FWP | Free writing prospectus | Jul 24, 2025 | — |
| FWP | Free writing prospectus | Jul 23, 2025 | — |
| 424B5 | Prospectus supplement | Jul 23, 2025 | — |
| F-3ASR | Filing | Jul 23, 2025 | — |
| 6-K | Current report (foreign issuer) | Jul 22, 2025 | Jul 22, 2025 |
| 6-K | Current report (foreign issuer) | Jun 11, 2025 | Jun 11, 2025 |
| 6-K | Current report (foreign issuer) | Jun 2, 2025 | Mar 31, 2025 |
| 6-K | Current report (foreign issuer) | Apr 29, 2025 | Apr 29, 2025 |
| 6-K | Current report (foreign issuer) | Apr 22, 2025 | Apr 22, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 11, 2025 | — |
| S-8 | Employee stock plan registration | Mar 24, 2025 | — |
| 20-F | Annual report (foreign issuer) | Mar 24, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Mar 24, 2025 | Dec 31, 2024 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 14, 2025 | — |
| 6-K | Current report (foreign issuer) | Jan 10, 2025 | Jan 10, 2025 |
| 6-K | Current report (foreign issuer) | Dec 23, 2024 | Dec 23, 2024 |
| EFFECT | Filing | Nov 26, 2024 | — |
| CORRESP | Letter to the SEC | Nov 25, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 19, 2024 | Nov 19, 2024 |
| F-3 | Shelf registration (foreign issuer) | Nov 19, 2024 | — |
| 6-K | Current report (foreign issuer) | Nov 14, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 6-K | Current report (foreign issuer) | Oct 3, 2024 | Oct 3, 2024 |
| 6-K | Current report (foreign issuer) | Oct 3, 2024 | Oct 3, 2024 |
| 6-K | Current report (foreign issuer) | Sep 26, 2024 | Sep 26, 2024 |
| 6-K | Current report (foreign issuer) | Sep 25, 2024 | Sep 25, 2024 |
| 6-K | Current report (foreign issuer) | Sep 9, 2024 | Sep 9, 2024 |
| 6-K | Current report (foreign issuer) | Sep 9, 2024 | Jun 30, 2024 |
| 6-K | Current report (foreign issuer) | Aug 6, 2024 | Aug 6, 2024 |
| 6-K | Current report (foreign issuer) | Jul 16, 2024 | Jul 15, 2024 |
| 6-K | Current report (foreign issuer) | Jun 4, 2024 | Jun 4, 2024 |
| 6-K | Current report (foreign issuer) | May 7, 2024 | May 7, 2024 |
| SC 13G | Ownership over 5% (passive) | Apr 19, 2024 | — |
| 20-F | Annual report (foreign issuer) | Apr 5, 2024 | Dec 31, 2023 |
| 6-K | Current report (foreign issuer) | Apr 2, 2024 | Apr 2, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| 6-K | Current report (foreign issuer) | Feb 2, 2024 | Feb 2, 2024 |
| 6-K | Current report (foreign issuer) | Jan 22, 2024 | Jan 22, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 22, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Oct 30, 2023 | — |
| SC 13D | Ownership over 5% (active) | Oct 30, 2023 | — |
| 424B4 | Prospectus | Oct 23, 2023 | — |
| SEC STAFF LETTER | Filing | Oct 20, 2023 | — |
| FWP | Free writing prospectus | Oct 20, 2023 | — |
| EFFECT | Filing | Oct 19, 2023 | — |
| EFFECT | Filing | Oct 19, 2023 | — |
| CERT | Filing | Oct 19, 2023 | — |
| 8-A12B | Filing | Oct 18, 2023 | — |
| CORRESP | Letter to the SEC | Oct 18, 2023 | — |
| CORRESP | Letter to the SEC | Oct 18, 2023 | — |
| CORRESP | Letter to the SEC | Oct 18, 2023 | — |
| F-1/A | Filing | Oct 18, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2023 | — |
| CORRESP | Letter to the SEC | Oct 16, 2023 | — |
| F-1/A | Filing | Oct 16, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2023 | — |
| F-6 | Filing | Oct 3, 2023 | — |
| CORRESP | Letter to the SEC | Sep 29, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Sep 29, 2023 | — |
| SEC STAFF LETTER | Filing | Sep 20, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2023 | — |
| DRSLTR | Filing | Sep 8, 2023 | — |
| DRS/A | Filing | Sep 8, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2023 | — |
| DRSLTR | Filing | Jul 28, 2023 | — |
| DRS/A | Filing | Jul 28, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2023 | — |
| DRS | Filing | Dec 16, 2022 | — |
Showing 105 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABVX (Nasdaq), AAVXF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Paris
- SEC filer status
- Accelerated filer, Emerging growth company
- SEC CIK
- 1956827
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.